IBDEI12R ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17462,1,3,0)
 ;;=3^Clubbing of Fingers
 ;;^UTILITY(U,$J,358.3,17462,1,4,0)
 ;;=4^R68.3
 ;;^UTILITY(U,$J,358.3,17462,2)
 ;;=^5019553
 ;;^UTILITY(U,$J,358.3,17463,0)
 ;;=R73.01^^61^787^93
 ;;^UTILITY(U,$J,358.3,17463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17463,1,3,0)
 ;;=3^Impaired Fasting Glucose
 ;;^UTILITY(U,$J,358.3,17463,1,4,0)
 ;;=4^R73.01
 ;;^UTILITY(U,$J,358.3,17463,2)
 ;;=^5019561
 ;;^UTILITY(U,$J,358.3,17464,0)
 ;;=R73.02^^61^787^94
 ;;^UTILITY(U,$J,358.3,17464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17464,1,3,0)
 ;;=3^Impaired Glucose Tolerance (oral)
 ;;^UTILITY(U,$J,358.3,17464,1,4,0)
 ;;=4^R73.02
 ;;^UTILITY(U,$J,358.3,17464,2)
 ;;=^5019562
 ;;^UTILITY(U,$J,358.3,17465,0)
 ;;=R73.09^^61^787^18
 ;;^UTILITY(U,$J,358.3,17465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17465,1,3,0)
 ;;=3^Abnormal Glucose NEC
 ;;^UTILITY(U,$J,358.3,17465,1,4,0)
 ;;=4^R73.09
 ;;^UTILITY(U,$J,358.3,17465,2)
 ;;=^5019563
 ;;^UTILITY(U,$J,358.3,17466,0)
 ;;=R73.9^^61^787^88
 ;;^UTILITY(U,$J,358.3,17466,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17466,1,3,0)
 ;;=3^Hyperglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,17466,1,4,0)
 ;;=4^R73.9
 ;;^UTILITY(U,$J,358.3,17466,2)
 ;;=^5019564
 ;;^UTILITY(U,$J,358.3,17467,0)
 ;;=R76.11^^61^787^146
 ;;^UTILITY(U,$J,358.3,17467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17467,1,3,0)
 ;;=3^Positive PPD
 ;;^UTILITY(U,$J,358.3,17467,1,4,0)
 ;;=4^R76.11
 ;;^UTILITY(U,$J,358.3,17467,2)
 ;;=^5019570
 ;;^UTILITY(U,$J,358.3,17468,0)
 ;;=R79.1^^61^787^3
 ;;^UTILITY(U,$J,358.3,17468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17468,1,3,0)
 ;;=3^Abnormal Coagulation Profile
 ;;^UTILITY(U,$J,358.3,17468,1,4,0)
 ;;=4^R79.1
 ;;^UTILITY(U,$J,358.3,17468,2)
 ;;=^5019591
 ;;^UTILITY(U,$J,358.3,17469,0)
 ;;=R82.5^^61^787^73
 ;;^UTILITY(U,$J,358.3,17469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17469,1,3,0)
 ;;=3^Elevated Urine Levels of Drug/Meds/Biol Subst
 ;;^UTILITY(U,$J,358.3,17469,1,4,0)
 ;;=4^R82.5
 ;;^UTILITY(U,$J,358.3,17469,2)
 ;;=^5019605
 ;;^UTILITY(U,$J,358.3,17470,0)
 ;;=R82.6^^61^787^29
 ;;^UTILITY(U,$J,358.3,17470,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17470,1,3,0)
 ;;=3^Abnormal Urine Levels of Subst of Nonmed Source
 ;;^UTILITY(U,$J,358.3,17470,1,4,0)
 ;;=4^R82.6
 ;;^UTILITY(U,$J,358.3,17470,2)
 ;;=^5019606
 ;;^UTILITY(U,$J,358.3,17471,0)
 ;;=R82.90^^61^787^28
 ;;^UTILITY(U,$J,358.3,17471,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17471,1,3,0)
 ;;=3^Abnormal Urine Findings,Unspec
 ;;^UTILITY(U,$J,358.3,17471,1,4,0)
 ;;=4^R82.90
 ;;^UTILITY(U,$J,358.3,17471,2)
 ;;=^5019609
 ;;^UTILITY(U,$J,358.3,17472,0)
 ;;=R82.91^^61^787^52
 ;;^UTILITY(U,$J,358.3,17472,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17472,1,3,0)
 ;;=3^Chromoabnormalities of Urine NEC
 ;;^UTILITY(U,$J,358.3,17472,1,4,0)
 ;;=4^R82.91
 ;;^UTILITY(U,$J,358.3,17472,2)
 ;;=^5019610
 ;;^UTILITY(U,$J,358.3,17473,0)
 ;;=R89.9^^61^787^22
 ;;^UTILITY(U,$J,358.3,17473,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17473,1,3,0)
 ;;=3^Abnormal Organ/Tissue Specimen Findings,Unspec
 ;;^UTILITY(U,$J,358.3,17473,1,4,0)
 ;;=4^R89.9
 ;;^UTILITY(U,$J,358.3,17473,2)
 ;;=^5019702
 ;;^UTILITY(U,$J,358.3,17474,0)
 ;;=R90.0^^61^787^102
 ;;^UTILITY(U,$J,358.3,17474,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17474,1,3,0)
 ;;=3^Intracranial Space-Occupying Lesion Dx Imaging of Central Nervous System
